权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel PET imaging agents for understanding glutamine addiction in cancer

用于了解癌症中谷氨酰胺成瘾的新型 PET 成像剂

基本信息

批准号：
8546312
负责人：
LEWIS A CHODOSH
金额：
$ 76.53万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-19 至 2016-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8546312
关键词：
2-Fluoro-2-deoxyglucose Acute Amino Acids Biodistribution Biological Biological Markers Cancer Biology Cancer Patient Cell Death Cells Clinic Collaborations Computational Biology Dependence Detection Development Diagnosis Down-Regulation ERBB2 gene Energy-Generating Resources Enzymes Evaluation Exhibits Gene Expression Genetic Genetically Engineered Mouse Glucose Glutamine Glycolysis Human Image Imaging Device Imaging technology In Vitro Individual Label Laboratories Lead Malignant Neoplasms Maps Mediating Metabolic Metabolic Marker Metabolic Pathway Metabolic stress Metabolism Methods Modeling Modification Molecular Molecular Target Monitor Mus Nutrient Nutritional Oncogenes Oncogenic PC3 cell line Paper Pathway interactions Pennsylvania Positron-Emission Tomography Preparation Radiopharmaceuticals Reporting Research Role Science Series Signal Pathway Source Specificity System Systems Biology Testing Tracer Transgenic Mice Translations Tumor Cell Line Universities Up-Regulation Writing addiction antitumor agent base c-myc Genes cancer cell cancer imaging cancer therapy cellular targeting clinically relevant in vivo malignant breast neoplasm molecular imaging mouse model neoplastic cell novel overexpression preference programs ras Oncogene response tumor tumor growth tumor metabolism uptake

项目摘要

This proposal is written in response to a RFA-CA-11-005 "Advanced In Vivo Imaging to Understand Cancer Systems". Based on the needs of the proposed integrated research a multiple- PI project will be used to maximize the potential of "team science" efforts on understanding of changes of cancer metabolism. The collaboration between Chosdosh and Kung labs in the University of Pennsylvania will provide a platform for integration of advanced in vivo PET imaging technologies with system biology approaches to understand in vivo imaging of cancer. The objective of this project is to prepare and evaluate 18F labeled glutamine derivatives for diagnosis of tumor growth in cancer patients and to investigate the cancer biology associated with the uptake of the novel tracers in cancer cells. In conjunction with positron emission tomography (PET) these new probes may provide imaging tools for studying re-programming of metabolic pathways for producing energy and building blocks to sustain proliferation of tumor cells. Due to changing nutrient needs associated to tumor metabolism and proliferation, there is a tumor specific increase in glycolysis and coordinated changes gene expression to maintain a high rate of metabolism. The increase in glycolysis in major tumor types has been demonstrated by FDG-PET. However, there is a significant fraction of active tumors that shows a negative FDG uptake suggesting that the FDG-negative tumors may be using alternative sources of energy and nutrient, such as glutamine and other amino acids. Recent reports indicate that there are tumor cells, such as SF188 cells that display a high c-myc gene expression, which leads to a high level of glutaminolysis. Reprogramming of genetic expression, up-regulation of the oncogenes, such as c-Myc, HER2/neu, Wnt, Ras and Akt, and shifting of the energy source associated with the proposed probes of tumor glutaminolysis and FDG-PET will be evaluated. We will develop methods to prepare a series of 18F labeled glutamines and specific fine-tuning of the oncogene expression in transgenic mice. The glutamines will be tested in tumor cells, such as 9L, C6, PC3 and SF188 cells, which have demonstrated propensity for higher amino acid uptake and glutaminolysis. Additionally, the tumor cell uptake will be correlated with oncogene expression through the use of conditional transgenic mouse models for c-MYC, HER2/neu, Wnt1, Ras and Akt overexpressing breast cancers. Successful glutamine imaging agents will be selected for PET imaging of transgenic mice the tumors, in which metabolic changes showing preference in using glutamine derivatives as the main source of nutrient. The proposed 18F labeled glutamines may serve as new metabolic markers for probing glutamine-addictive tumors not detected by FDG-PET. The development of the proposed alternative metabolic biomarkers provides an exciting opportunity for advancing diagnosis and treatment of tumor. The novel tumor metabolic imaging agents may lead to new methods to appraise the metabolic status of tumor growth in human cancer and provide advancement of our understanding of tumor oncogene expression and tumor metabolism by PET imaging.

本提案是根据RFA-CA-11-005“Advanced in Vivo Imaging to